Connect
← Return to Prostate Cancer, Stage 4, spine & pelvis, Eligard, now abiraterone
Discussion
Prostate Cancer, Stage 4, spine & pelvis, Eligard, now abiraterone
Prostate Cancer | Last Active: Oct 5 9:35am | Replies (34)Comment receiving replies
This article in JAMA shows a comparison of the Lutamides
Search this title and you will find the article
Androgen Receptor Inhibitors in Patients With Nonmetastatic
Castration-Resistant Prostate Cancer
The studies purpose is to find
‘What are the clinical use and outcomes of the androgen receptor inhibitors (ARIs) darolutamide, enzalutamide, and apalutamide in US patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)?”
This may not be as complete as we’d like to see, but it is a start of a comparison of the three products and favors Darolutamide.
And then the question comes up “if someone has their metastasis zapped with SBRT are they actually non-metastatic now”!!!??
While it refers to nmCRPC many doctors are suspecting that some people that are listed as non-metastatic actually are metastatic, just that the metastasis are too small to detect yet.
Replies to "This article in JAMA shows a comparison of the Lutamides Search this title and you will..."
Connect
Yes, I think that's the DEAR study I mentioned in my post for nmCRPC. It will be interesting when we have comparison studies of the *lutamides for my mCSPC and other scenarios, but until then, it's a bit tricky trying to extrapolate beyond what's actually been studied.
After all, one of the proven benefits of Apalutamide is delaying the progression from castrate sensitivity to castrate resistance for metastatic cancer in the first place (the TITAN study), while the DEAR study is about delaying the progression to metastatis. You're right that it could possibly end up that one *lutamide is better at both.